Association of mRNA versus inactivated Covid-19 vaccine responses with smoking in Multiple Sclerosis
Authors:
- 1 January 2023
- journal article
- research article
- Published by Turk Noropsikiyatri Dernegi in Archives of Neuropsychiatry
- Vol. 60 (3) , 252-256
Abstract
Introduction: Coronavirus disease 2019 (COVID-19) is the biggest health challenge of recent times. Studies so far reveal that vaccination is the only way to prevent this pandemic. There may be factors that decrease or increase vaccine effectiveness. In multiple sclerosis (MS), some of these factors may cause changes in the effectiveness of the vaccine, depending on the nature of the disease and disease-modifying treatments (DMT). In this study, we aimed to investigate the relationship between antibody titer and smoking in non-treated and DMT-treated MS patients who received inactivated vaccine (Sinovac) and messenger RNA BNT162b2 (BioNTech) mRNA vaccines.Method: Vaccine antibody responses were measured between 4-12 weeks after two doses of inactivated vaccine and mRNA vaccines. Patients were separated into 6 groups as: patients with MS without treatment PwMS w/o T, ocrelizumab, fingolimod, interferons (interferon beta-1a and interferon beta-1b), dimethyl fumarate, and teriflunomide. Antibody titers of smokers and non-smokers were compared for both vaccines and for each group.Results: The study included 798 patients. In the mRNA vaccine group, smokers (n=148; 2982 & PLUSMN;326 AU/mL) had lower antibody titers compared to the non-smokers (n=244; 5903 & PLUSMN;545 AU/mL) in total (p=0.020). In the inactivated vaccine group, no significant difference was detected between smokers (n=136; 383 & PLUSMN;51 AU/mL) and non-smokers (n=270; 388 & PLUSMN;49 AU/mL) in total (p=0.149). In both vaccine groups, patients receiving ocrelizumab and fingolimod had lower antibody titers than those receiving other DMTs or PwMS w/o T. In untreated MS patients, antibody levels in smokers were lower than in non-smokers in the mRNA vaccine group. No difference was found between antibody levels of smokers and non-smokers in any of the inactivated vaccine groups.Conclusion: Ocrelizumab and fingolimod have lower antibody levels than PwMS w/o T or other DMTs in both mRNA and inactivated vaccine groups. Smoking decreases antibody levels in the mRNA vaccine group, while it has no effect in the inactivated vaccine group.Keywords
This publication has 13 references indexed in Scilit:
- Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysisMultiple Sclerosis Journal, 2023
- Does smoking have an impact on the immunological response to COVID-19 vaccines? Evidence from the VASCO study and need for further studiesPublic Health, 2022
- Age and smoking predict antibody titers after the BNT162b2 COVID‐19 vaccineCancer, 2022
- Effect of Different Disease-Modifying Therapies on Humoral Response to BNT162b2 Vaccine in Sardinian Multiple Sclerosis PatientsFrontiers in Immunology, 2021
- Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple SclerosisNeurology, 2021
- SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort studyMultiple Sclerosis Journal, 2021
- The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?Multiple Sclerosis and Related Disorders, 2021
- Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID‐19 mRNA vaccineDiabetes/Metabolism Research and Reviews, 2021
- Disease‐Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple SclerosisAnnals of Neurology, 2021
- Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple SclerosisJAMA Neurology, 2020